Pierrel S.p.A.,
Pierrel is a global player in the pharmaceutical market, with over 70 years of experience in the field of oral care and listed at Euronext Milan of Borsa Italiana. Our legal and operational headquarters are in Capua, near Caserta and a few kilometers from Naples. The production facility received the first authorizations from the European Medicines Agency (EMA) in 1989 and from the Food and Drug Administration (FDA) in 2009 for the aseptic production of injectable drugs. Over the years, the core of our activity has been focused on the registration and marketing of dental anesthetics with Pierrel brand; including Orabloc, registered in the major international markets (including USA, Canada, Italy, Russia, Poland, Serbia, France, UK, Germany, Kosovo, Austria, Sudan, Taiwan and Indonesia).
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 1948
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About us
We are specialized in the production of dental anesthetics using aseptic technique and we work on a constant process of scouting the best medical devices for the dental sector, for which we follow directly the patent aspect, the industrialization and the commercialization, in collaboration with universities and research institutions.
Pierrel, a pharmaceutical company since 1948
Based in Capua (CE), listed on the Euronext Milan Stock Exchange, Pierrel is authorized by EMA and FDA for the aseptic production of injectable drugs. After more than seventy years of experience, Pierrel is one of the world’s leading manufacturers of dental anesthetics with its own brand, including Orabloc, sold in most of the world markets and which has reached a relevant market share in the USA.
Italian quality and innovation for the oral health
We are specialized in the production, development, registration and licensing of dental anesthetics and medical devices for oral care.
Today, thanks to the FDA’s approval, we have a significant market share in the USA and we have numerous registrations going on all over the world. We also are specialized in dental research, development and distribution of medical devices.
We are one of the world’s leading manufacturers of dental anesthetics.
Our Philosophy
To produce with quality respecting the environment.
To respond promptly to the needs of the market, to pursue with tenacity the goals of international expansion, to ensure a healthy and stimulating working environment for our employees, all seasoned by passion and Italian genius.
Our Mission
We produce in Italy dental anesthetics, using advanced technologies and providing to dentists all over the world innovative products for the prevention and treatment of oral diseases.
Our Vision
To become a benchmark for dental anesthesia and for innovative solutions for oral health.
The Pierrel production
We are specialized in aseptic production of dental anaesthetics, in compliance with high international quality standards and with the adoption of cutting-edge technologies.
The site
The production site and the headquarters are in Capua, in the south of Italy, a few kilometers from Naples. The production site is spread over an area of 40,000 sqm, of which 11.000 mq dedicated to the plant, 5500 mq to the productive departments, while the remaining areas are used as warehouse (with possibility to conserve in premises to different temperatures, to 2-8°C, 15°C and 25°C) chemical and microbiological laboratories as well as offices and facilities.
We are authorized by EMA (European Medicines Agency) and FDA (Food & Drug Administration) to produce aseptic dental anesthetics.
Pierrel Quality Compliance
The production is supported by an organized company quality system with different objectives:
- meet the therapeutic requirements;
- meet the requirements of the customer;
- develop and produce devices in full compliance with the reference standards (EU-GMP FDA regulation).
The Capua plant has AIFA’s Good Manufacturing Practice (GMP) approval and that of the main drug authorities in the major international markets: EMA, FDA, Ministry of Health and Welfare (Taiwan), Ministry of Industry and Trade of the Russian Federation, Health Canada and more.
The compliance of the plant with the reference standards is confirmed periodically by inspections and controls, while for the environmental management system we are in possession of the UNI EN ISO 140018 (SGS) Certification since 2002. This legislation, which lays down the necessary requirements to develop our environmental performance in order to make us active promoters of sustainable development, is adopted not only in the production field, but in general in all business activities.
The principles that guide our company choices are as follows:
- making environment respect a priority in our business strategies;
- to undertake to inform, train and motivate our staff and suppliers to carry out their work in a safe and environmentally responsible way;
- ensuring a healthy and safe working environment for our employees;
- pursue a total control of the production process to ensure a safe and quality product for patients.
- innovate and work with a view to lean production to aim at the excellence of all business processes;
Innovation
At Pierrel we are involved in a scouting process of the best solutions for dentists.
We take care of the patent aspect, the process of industrialization and subsequent marketing of products with such a degree of innovation able to meet the needs of professionals and patients.
Together to innovate
Our goal is to make innovations accessible to oral care professionals. We are committed to collaborating with universities and research institutions around the world.
Our Markets
An Italian quality, exported all over the world. In over 70 years of experience, we have obtained numerous marketing authorisations worldwide, from Canada to Taiwan. Today, we seek and develop increasingly innovative solutions, determined to become major players in all international markets.
- 40 MARKET AUTHORISATIONS
- 32 COUNTRIES